Abstract:Photodynamic therapy (PDT) is a promising strategy for cancer treatment. It can not only generate reactive oxygen species (ROS) to cause the chemical damage of tumor cells in the presence of enough oxygen but also promote the antitumor immunity of T cells through enhancing the production of interferon γ (IFN-γ). However, one phenomenon is ignored so far that the enhanced production of IFN-γ caused by PDT may significantly increase the expression of programmed death-ligand 1 (PD-L1) on the tumor cell membrane and thus could inhibit the immune killing effects of T cells. Herein, we report the construction of a composite by loading metformin (Met) and IR775 into a clinically usable liposome as a two-in-one nanoplatform (@Lip) to solve this problem. The @Lip could reverse tumor hypoxia to enhance ROS production to elicit more chemical damage. Besides, the overexpression of PD-L1 by PDT was also effectively down-regulated. These therapeutic benefits including decreased PD-L1 expression, alleviated T cell exhaustion, and reversed tumor hypoxia successfully suppressed both the primary and abscopal tumor growth in bladder and colon cancers, respectively. Combining with its excellent biocompatibility, our results indicate that this @Lip system has great potential to become a highly effective cancer therapy modality.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c21743?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c21743</a>.UV–vis spectra of Met, , IR775, and ; dilution and storage stability analysis of @Lip; chromatogram of Met; standard curve of Met and IR775; cellular uptake of @Lip; representative immunofluorescence images of pimonidazole; flow cytometry results of ROS in MB49 cells; cell viability of CT26 cells after different treatments; immunofluorescence images of PD-L1 in MB49 and CT26 cells; Western blot analysis of the expression of PD-L1 in MB49 and CT26 cells; flow cytometry analysis of the expression of PD-L1 in MB49 and CT26 cells; analysis of the expression of PD-L1 in the CT26 tumor model by Western blotting; immunofluorescence images of CD3+, CD4+, and CD8+ T cells in CT26 tumors; expression of IFN-γ in the MB49 and CT26 tumor tissues; photograph of collected MB49 and CT26 tumors after different treatments; relative body weight of MB49 and CT26 tumor-bearing mice after different treatments; representative images of Ki67, TUNEL, and H&E staining in the MB49 and CT26 tumors after different treatments; expression of IFN-γ in the MB49 tumor tissues after antitumor treatment; biosafety evaluation of @Lip; The primary tumor growth curves for MB49 tumor-bearing mice after different treatments; distal tumor growth curves of each mouse in different treatment groups (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c21743/suppl_file/am0c21743_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma.

Multifunctional Immunoliposomes Enhance the Immunotherapeutic Effects of PD‐L1 Antibodies against Melanoma by Reprogramming Immunosuppressive Tumor Microenvironment

Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy

Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy

Dual mitigation of immunosuppression combined with photothermal inhibition for highly effective primary tumor and metastases therapy

Photothermal Therapy Mediated by Phase-Transformation Nanoparticles Facilitates Delivery of Anti-Pd1 Antibody and Synergizes with Antitumor Immunotherapy for Melanoma

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy

A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis.

Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief

Hypoxia-responsive Immunostimulatory Nanomedicines Synergize with Checkpoint Blockade Immunotherapy for Potentiating Cancer Immunotherapy

Microfluidic PLGA microcapsules with PD-L1 aptamers and docetaxel encapsulation for enhancing tumor immunity

PD-L1 antibody conjugated dihydrotanshinone I-loaded polymeric nanoparticle for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects

A Multifunctional Nanoparticle Dual Loading with Chlorin e6 and STING Agonist for Combinatorial Therapy of Melanoma

Reversing Immune Suppression and Potentiating Photothermal Immunotherapy Via Bispecific Immune Checkpoint Inhibitor Loaded Hollow Polydopamine Nanospheres

A clinically acceptable strategy for sensitizing anti-PD-1 treatment by hypoxia relief

Multifunctional polymeric micelle-based chemo-immunotherapy with immune checkpoint blockade for efficient treatment of orthotopic and metastatic breast cancer

Functional co-delivery nanoliposomes based on improving hypoxia for increasing photoimmunotherapy efficacy of cold tumors

Novel combination strategy of high intensity focused ultrasound (HIFU) and checkpoint blockade boosted by bioinspired and oxygen-supplied nanoprobe for multimodal imaging-guided cancer therapy

A carbon dot-doped Cu-MOF-based smart nanoplatform for enhanced immune checkpoint blockade therapy and synergistic multimodal cancer therapy